View source for General discusson on use of analgesics

In my experience, in commercial drug development work, the main worries have been with the incidental use of NSAIDs for clinical purposes in long term studies with "immunomodulator" test materials. The point of friction is usually at the interface with the client rather than with internal stakeholders. In my experience again, this has always been managed properly, even at the expense of the client relationship.
Obviously there are potential interferences with many other study types, but clearly defined humane end points seem to deal with most of these adequately.